Ronald Shazer

Publication Activity (10 Years)

Years Active: 2022-2023
Publications (10 Years): 2

Top Topics

Smoking Cessation

Endoplasmic Reticulum Stress

Acute Myeloid Leukemia

Ejection Fraction

Top Venues

Science translational medicine

Cancer discovery

This page only lists publications with an associated author ORCID identifier.

Publications

Lars D Engstrom, Ruth Aranda, Laura Waters, Krystal Moya, Vickie Bowcut, Laura Vegar, David Trinh, Allan Hebbert, Christopher R Smith, Svitlana Kulyk, J David Lawson, Quanyuan He, Laura D Hover, Julio Fernandez-Banet, Jill Hallin, Darin Vanderpool, David M Briere, Alice Blaj, Matthew A Marx, Jordi Rodon Ahnert, Michael D Offin, Kathryn C Arbour, Melissa Lynne Johnson, David J Kwiatkowski, Pasi A Janne, Candace L Haddox, Kyriakos P Papadopoulos, Jason T Henry, Konstantinos Leventakos, James G Christensen, Ronald Shazer, Peter Olson
MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP deleted cancer. Cancer discovery (2023)
Pavlos Msaouel, Sangeeta Goswami, Peter F Thall, Xuemei Wang, Ying Yuan, Eric Jonasch, Jianjun Gao, Matthew T Campbell, Amishi Yogesh Shah, Paul Gettys Corn, Alda L Tam, Kamran Ahrar, Priya Rao, Kanishka Sircar, Lorenzo Cohen, Sreyashi Basu, Fei Duan, Sonali Jindal, Yuwei Zhang, Hong Chen, Shalini Singh Yadav, Ronald Shazer, Hirak Der-Torossian, James P Allison, Padmanee Sharma, Nizar M Tannir
A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy. Science translational medicine 14 (641) (2022)